乌司他丁对慢性阻塞性肺疾病患者血清COX-2, PLA-2 及肺功能的影响

目的:探讨乌司他丁对慢性阻塞性肺疾病(COPD)患者血清环氧合酶-2(COX-2)、磷脂酶A2(PLA-2)及肺功能的影响。方法:选取2015年1月至2016年1月我院收治的82例COPD患者,随机分为观察组和对照组。对照组患者采取COPD常规处理,观察组在对照组的基础上给予乌司他丁,检测两组患者治疗前后的COX-2、PLA-2以及肺功能指标FEV1、FVC及FEV1/FVC。结果:治疗前,观察组和对照组的COX-2、PLA-2水平均无统计学差异(P0.05);治疗后,观察组和对照组的COX-2、PLA-2均比治疗前显著降低,且观察组低于同期对照组,差异均有统计学意义(P0.05)。治疗前,两组患者各项肺功能指标均无统计学差异(P0.05);治疗后,观察组的FEV1、FVC及FEV1/FVC均优于对照组(P0.05)。结论:乌司他丁能够有效降低COPD患者血清COX-2、PLA-2浓度,改善肺功能。

Effect of Ulinastatin on the SerumLevels of COX-2, PGE2 and Pulmonary Function of Patients with COPD

Objective:To investigate the effects of ulinastatin on the serum levels of cyclooxygenase-2 (COX-2), phospholipase A2 (PLA2) and pulmonary punction of patients with chronic obstructive pulmonary disease (COPD).Methods:82 patients with COPD were randomly selected in our hospital from January 2015 to January 2016 and divided into the observation group and the control group. The control group was given routine treatment, and the observation group was given ulinastatin treatment. Then the serum levels of COX-2, PLA2, and FEV1, FVC as well as FEV1/FVC in both groups were detected and compared before and after the treatment.Results:Before treatment, no statistical difference was found in the COX-2 and PLA-2 levels between the observation group and the control group (P>0.05). After treatment, the serum levels of COX-2 and PLA2 in both groups were significantly lower than those before treatment(P<0. 05), which were significantly lower in the observation group than those of the control group (P<0.05). Before treatment, no statistical difference was found in the FEV1, FVC, and FEV1/FVC levels between two groups (P>0.05). After treatment, the FEV1, FVC, and FEV1/FVC of observation group were significantly better than those in the control group (P<0.05).Conclusion:Ulinastatin could effectively reduce the serumlevel of COX-2 and PLA-2 in the patients with COPD and improve lung function.